Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.46 |
| ▸ | STK10 | O94804 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.46 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683392 | 0.87 | KDR (0.83) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683441 | 0.87 | KDR (0.67) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683393 | 0.86 | KDR (0.68) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683408 | 0.85 | KDR (0.72) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683394 | 0.85 | KDR (1.00) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683435 | 0.85 | KDR (1.00) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683397 | 0.85 | KDR (1.00) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683463 | 0.85 | KDR (0.82) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683465 | 0.85 | KDR (0.82) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1683460 | 0.85 | KDR (0.82) | KDRCYP3A4KCNH2FGFR1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | claimed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | claimed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | claimed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDR 5/4885CYP3A4 1437/4885KCNH2 3157/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDR 5/4885CYP3A4 1479/4885KCNH2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.